<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009410</url>
  </required_header>
  <id_info>
    <org_study_id>M13-954</org_study_id>
    <secondary_id>2013-001347-31</secondary_id>
    <nct_id>NCT02009410</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2</brief_title>
  <official_title>A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nuvisan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Datamap</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ClinIntel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catalent</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion
      of fat, sugars and proteins) in diabetes type II
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery rate of 13CO2 (carbon dioxide with stable isotope of carbon)</measure>
    <time_frame>from baseline up to the week 12 visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in nutritional parameters</measure>
    <time_frame>from baseline up to the week 12 visit</time_frame>
    <description>fat soluble vitamins (D and E), retinol-binding protein, albumin, pre-albumin, magesium and calcium will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>from baseline up to the week 12 visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life assessed via a questionnaire Gastrointestinal-Quality of Life Index (GIQL)</measure>
    <time_frame>from baseline up to the week 12 visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical global impression of disease symptoms</measure>
    <time_frame>from baseline up to the week 12 visit</time_frame>
    <description>disease symptoms will be rated by the subject according a rating scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>vital signs</measure>
    <time_frame>from baseline up to the week 12 visit</time_frame>
    <description>blood pressure and heart rate, body weight and BMI</description>
  </other_outcome>
  <other_outcome>
    <measure>routine safety laboratory</measure>
    <time_frame>from baseline up to the week 12 visit</time_frame>
    <description>Hematology, biochemistry and a urine pregnancy test will be performed</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Creon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creon</intervention_name>
    <description>Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks</description>
    <arm_group_label>Creon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creon 25000 matching Placebo</intervention_name>
    <description>Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent

          -  BMI &lt; 30 kg/m2

          -  History of type 2 diabetes mellitus as confirmed by:

          -  onset of diabetes after 30 years of age and

          -  no insulin treatment in the first year after diagnosis

          -  Subjects on insulin treatment or on insulin treatment in combination with oral
             antidiabetics

          -  HbA1c &gt; 6.5% in medical history within the last 6 months despite insulin treatment

          -  Not previously treated with any pancreatic enzyme supplementation

        Inclusion Criterion at Visit 1:

        • FE-1 (fecal elastase 1) &lt;100μg/g of stool

        Inclusion Criterion at Visit 2:

        • 13C MTBT of &lt;29% 13CO2-CRR (Carbon dioxide-Cumulative Recovery Rate)

        Exclusion Criteria:

          -  Treatment with systemic steroids for at least 3 weeks within past 6 months

          -  Patients with a known pancreatic exocrine insufficiency due to non-diabetic diseases,
             e.g., chronic pancreatitis, pancreatectomy, cystic fibrosis, celiac disease,
             shwachman-diamond syndrome, gastrectomy, etc.

          -  Any type of malignancy involving digestive tract in the last 5 years

          -  Any type of gastrointestinal surgery (except appendectomy and gallbladder resection)

          -  Short bowel syndrome

          -  Hemochromatosis

          -  Known late onset autoimmune diabetes in the adult

          -  Any history of drug abuse including alcohol

          -  Positive urine pregnancy test; lactation; females of child-bearing potential who are
             not using either an oral hormonal contraceptive or an intrauterine device

          -  Hypersensitivity to the active substance or to any of the excipients

          -  Intake of an experimental drug within 4 weeks prior to entry into this study

          -  Suspected non-compliance or non-cooperation

          -  History of human immunodeficiency virus (HIV) infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suntje Sander-Struckmeier, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site reference no. 113456</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 113477</name>
      <address>
        <city>Frankfurt</city>
        <zip>60594</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 113476</name>
      <address>
        <city>Pohlheim</city>
        <zip>35415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 113475</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 112519</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 112520</name>
      <address>
        <city>Málaga</city>
        <zip>29071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 112495</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 112518</name>
      <address>
        <city>Segovia</city>
        <zip>40002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 112496</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 112517</name>
      <address>
        <city>Ávila</city>
        <zip>05004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <last_update_submitted>June 19, 2014</last_update_submitted>
  <last_update_submitted_qc>June 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exocrine Pancreatic Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

